New therapeutics are urgently needed in the fight against COVID-19. Repurposing drugs that are either already approved for human use or are in advanced stages of the approval process can facilitate more rapid advances toward this goal. ABSTRACT By late 2020, the coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), had caused tens of millions of infections and over 1 million deaths worldwide. A protective vaccine and more effective therapeutics are urgently needed. We evaluated a new poly(ADP-ribose) polymerase (PARP) inhibitor, stenoparib, that recently advanced to phase II clinical trials for treatment of ovarian cancer, for activity against human respiratory coronaviruses, including SARS-CoV-2, in vitro . Stenoparib exhibits dose-dependent suppression of SARS-CoV-2 multiplication and spread in Vero E6 monkey kidney and Calu-3 human lung adenocarcinoma cells. Stenoparib was also strongly inhibitory to the human seasonal respiratory coronavirus HCoV-NL63. Compared to remdesivir, which inhibits viral replication downstream of cell entry, stenoparib impedes entry and postentry processes, as determined by time-of-addition (TOA) experiments. Moreover, a 10 μM dosage of stenoparib—below the approximated 25.5 μM half-maximally effective concentration (EC 50 )—combined with 0.5 μM remdesivir suppressed coronavirus growth by more than 90%, indicating a potentially synergistic effect for this drug combination. Stenoparib as a stand-alone or as part of combinatorial therapy with remdesivir should be a valuable addition to the arsenal against COVID-19.
【저자키워드】 COVID-19, SARS-CoV-2, NL63, PARP, stenoparib, 【초록키워드】 Treatment, coronavirus disease, Coronavirus disease 2019, Coronaviruses, Vaccine, coronavirus, clinical trial, pandemic, therapy, Infection, Remdesivir, repurposing, drug, in vitro, severe acute respiratory syndrome Coronavirus, kidney, Spread, Viral, cells, viral replication, human lung, death, lung adenocarcinoma, PARP, stenoparib, respiratory, inhibitor, Calu-3, Protective, HCoV-NL63, Concentration, ovarian cancer, Vero E6, determined by, synergistic effect, acute respiratory syndrome, acute respiratory syndrome coronavirus, acute respiratory syndrome coronavirus 2, growth, dosage, cell entry, drug combination, Stage, approval, Calu, polymerase, downstream, inhibitory, arsenal, effective, synergistic, Respiratory Coronavirus, caused, addition, inhibit, evaluated, approved, facilitate, suppressed, dose-dependent, experiments, exhibit, New, impede, 【제목키워드】 Human, stenoparib, HCoV-NL63, block, the SARS-CoV-2,